Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials

References

• Sabat R, Jemec GBE, Matusiak Ł, et al. Hidradenitis suppurativa. Nat Rev Dis Prim. 2020;6(1).DOI:10.1038/s41572-020-0149-1
   PubMed Web of Science ®Google Scholar
• Velpeau A. Dictionnaire de Médecine. Vol 2. In: Bechet Jeune Z, editor. Paris: Repertoire générale des Sciences Medicals sous le rapport theorique et pratique; 1839.
   Google Scholar
• Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990–998.
   PubMed Web of Science ®Google Scholar
• Jemec G, Gniadecka M. Ultrasound examination of hair follicles in hidradenitis suppurativa. Arch Dermatol. 1997;133(8):967–970.
   PubMedGoogle Scholar
• Donsky H, Mendelson C. Squamous cell carcinoma as a complication of hidradenitis suppurativa. Arch Dermatol. 1964;90(5):488–491.
   PubMedGoogle Scholar
• Yu C, Cook M. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122(6):763–769.
   PubMed Web of Science ®Google Scholar
• von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad DERMATOLOGY Venereol. 2000;14(5):389–392.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Nogueira da Costa A, Fimmel S, et al. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol. 2020;34(7):1555–1563.
   PubMed Web of Science ®Google Scholar
• Yazdanyar S, Jemec GBE. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis. 2011;24(2):118–123.
   PubMed Web of Science ®Google Scholar
• Naik HB, Nassif A, Ramesh MS, et al. Are bacteria infectious pathogens in hidradenitis suppurativa? Debate at the symposium for hidradenitis suppurativa advances meeting, November 2017. J Invest Dermatol. 2019;139(1):13–16.
   PubMed Web of Science ®Google Scholar
• Lim SYD, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019;13:53–78.
   PubMed Web of Science ®Google Scholar
• Frew JW, Marzano AV, Wolk K, et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2020;141:316–324.e2.
   PubMed Web of Science ®Google Scholar
• Reguiaï Z, Fougerousse AC, Maccari F, et al. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):e750–e751.
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611.
   PubMed Web of Science ®Google Scholar
• Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83:1341–1348.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatology Venereol. 2019;33(1):19–31.
   PubMed Web of Science ®Google Scholar
• Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642–650.
   PubMed Web of Science ®Google Scholar
• van Tulder M, Furlan A, Bombardier C, et al. Updated method guidelines for systematic reviews in the cochrane collaboration back review group. Spine. 2003;28(12):1290–1299.
   PubMed Web of Science ®Google Scholar
• Béliveau A, Boyne DJ, Slater J, et al. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol. 2019;19(1):196.
   PubMed Web of Science ®Google Scholar
• RStudio Team. RStudio:Integrated Development for R. Published online 2015. Available from: https://support.rstudio.com/hc/en-us/articles/206212048-Citing-RStudio
   Google Scholar
• Clemmensen O. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325–328.
   PubMed Web of Science ®Google Scholar
• Jemec G, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–974.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205–217.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398.
   PubMed Web of Science ®Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52–59.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434.
   PubMed Web of Science ®Google Scholar
• Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 Targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138(4):795–801.
   PubMed Web of Science ®Google Scholar
• Grimstad Ø, Kvammen BØ, Swartling C. Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study. Am J Clin Dermatol. 2020;21(5):741–748.
   PubMed Web of Science ®Google Scholar
• UCB Biopharma SRL. A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppurativa. Eur Union Clin Trials Regist. Published online 2019. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000892-10/results
   Google Scholar
• Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52–59.
   PubMed Web of Science ®Google Scholar
• Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35(8):1188–1198.
   PubMed Web of Science ®Google Scholar
• Adams DR, Yankura JA, Fogelberg AC, et al. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501–504.
   PubMedGoogle Scholar
• Highton L, Chan W-Y, Khwaja N, et al. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128(2):459–465.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12):846–855.
   PubMed Web of Science ®Google Scholar
• Vossen AV, van Doorn MBA, van der Zee HH, et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–88.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum K, Crouse L, Dong L, et al. Intralesional triamcinolone may not be beneficial for treating acute hidradenitis suppurativa lesions: a double-blind, randomized, placebo-controlled trial. Dermatol Surg. 2020;46(5):685–689.
   PubMed Web of Science ®Google Scholar
• Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62(4):637–645.
   PubMed Web of Science ®Google Scholar
• Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol. 2015;40(2):116–122.
   PubMed Web of Science ®Google Scholar
• Wilden S, Friis M, Tuettenberg A, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatolog Treat. 2019;32:1–8.
   Web of Science ®Google Scholar
• Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with Intravenous Infusion: results in hidradenitis suppurativa. Dermatology. 2020;236(1):21–24.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Kuriyama A. How often do systematic reviews exclude articles not published in English? J Gen Intern Med. 2019;34(8):1388–1389.
   PubMed Web of Science ®Google Scholar
• Li T, Puhan MA, Vedula SS, et al. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 2011;9(1):2–5.
   PubMedGoogle Scholar
• Veroniki AA, Straus SE, Rücker G, et al. Is providing uncertainty intervals in treatment ranking helpful in a network meta-analysis? J Clin Epidemiol. 2018;100:122–129.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N, Sundaram M, Teixeira H, et al. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016;22(3). DOI:10.5070/D3223030360
   Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatology Venereol. 2015;29(4):619–644.
   PubMed Web of Science ®Google Scholar
• Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990;13(4):227–236.
   PubMed Web of Science ®Google Scholar
• Minor V, Marris CK, McGorray SP, et al. Effects of preoperative ibuprofen on pain after separator placement. Am J Orthod Dentofacial Orthop. 2009;136(4):510–517.
   PubMed Web of Science ®Google Scholar
• Salmassian R, Oesterle LJ, Shellhart WC, et al. Comparison of the efficacy of ibuprofen and acetaminophen in controlling pain after orthodontic tooth movement. Am J Orthod Dentofacial Orthop. 2009;135(4):516–521.
   PubMed Web of Science ®Google Scholar
• Cheng C, Xie T, Wang J. The efficacy of analgesics in controlling orthodontic pain: a systematic review and meta-analysis. BMC Oral Health. 2020;20(1):259.
   PubMed Web of Science ®Google Scholar
• Gould D, Kelly D, Goldstone L, et al. Examining the validity of pressure ulcer risk assessment scales: developing and using illustrated patient simulations to collect the data. J Clin Nurs. 2001;10(5):697–706.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175(2):263–272.
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156(5):945–950.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Collier F, Brown D, et al. British association of dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180(5):1009–1017.
   PubMed Web of Science ®Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90.
   PubMed Web of Science ®Google Scholar
• Hendricks AJ, Hsiao JL, Lowes MA, et al. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96.
   PubMed Web of Science ®Google Scholar
• Narla S, Lyons AB, Hamzavi IH. The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res. 2020;9:1049.
   Google Scholar
• Magalhães RF, Rivitti-Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa – Brazilian society of dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):7–19.
   PubMed Web of Science ®Google Scholar
• Ovadja ZN, Schuit MM, Horst CMAM, et al. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. Br J Dermatol. 2019;181(2):344–349.
   PubMed Web of Science ®Google Scholar
• Thorlacius L. Severity staging of hidradenitis suppurativa: is Hurley classification the answer? Br J Dermatol. 2019;181(2):243–244.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Hickish T, Wyrwicz L, et al. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2019;8(3):1551651.
   PubMed Web of Science ®Google Scholar
• Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56(4):624–628.
   PubMed Web of Science ®Google Scholar
• Lee RA, Dommasch E, Treat J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2009;60(4):565–573.
   PubMed Web of Science ®Google Scholar
• Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342–346.
   PubMed Web of Science ®Google Scholar
• Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149(6):732–735.
   PubMed Web of Science ®Google Scholar
• Anderson MD, Zauli S, Bettoli V, et al. Cyclosporine treatment of severe Hidradenitis suppurativa--A case series. J Dermatolog Treat. 2016;27(3):247–250.
   PubMed Web of Science ®Google Scholar
• Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050.
   PubMed Web of Science ®Google Scholar
• Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019;80(5):1314–1321.
   PubMed Web of Science ®Google Scholar
• Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with intravenous infusion: results in Hidradenitis suppurativa. Dermatology. 2020;236(1):21–24.
   PubMed Web of Science ®Google Scholar